- IN8bio Inc (NASDAQ:INAB) announced new data from the Phase 1 investigator-sponsored trial of INB-100 in leukemia patients.
- The data showed that 100% of evaluable patients (n=7) treated with INB-100 remained alive, progression-free, and in durable complete remission (CR) as of April 21, 2023.
- The latest data showed significant allogeneic gamma-delta T cell expansion and persistence in patients through the first 180 days post-treatment.
- Patients who received INB-100 treatment at Dose Level 2 exhibited an average of 82.9x greater gamma-delta T cell expansion at 60 days compared to patients undergoing haploidentical HSCT without INB-100 therapy.
- The gamma-delta T cell levels in Dose Level 2 patients are also, on average, 12.8x greater than those achieved in Dose Level 1, demonstrating a dose-response related to the gamma-delta T cell infusion. Elevations in CD4+, CD8+ T cells, NK cells and B cells have also been observed, indicating a broad positive immune response.
- The study’s updated safety data reported low-grade (1-2) graft versus host disease (GvHD) in all patients treated, which was steroid-responsive, and had a more rapid onset at higher dose levels.
- No dose-limiting toxicities have been observed.
- Price Action: INAB shares are 140% at $2.52 on the last check Monday.
What’s Happening With Lucid Stock Falling
Lucid Group Inc (NASDAQ: LCID) shares are trading lower by 7.78% to $7.52 Thursday afternoon. Shares of companies in the broader consumer discretionary sector are trading lower following strong jobless claims figures, which have added to concerns over a tight labor market.
